Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.2K
Introduction to Language of Pathophysiology ll01:17

Introduction to Language of Pathophysiology ll

40
This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...
40
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

6.8K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Outcomes of CD19 CAR-T Cell Therapy in Splenectomized Patients With B-Cell Lymphomas.

Transplantation and cellular therapy·2026
Same author

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study.

Hematological oncology·2026
Same author

Favorable safety and efficacy profiles of α-1-antitrypsin in steroid- and ruxolitinib-refractory acute graft-<i>versus</i>-host disease of the gastrointestinal tract: a retrospective, single center study.

Haematologica·2026
Same author

Local cytokine release syndrome with cervical angioedema following CAR-T cell therapy.

Haematologica·2026
Same author

Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.

Annals of hematology·2026
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026

Related Experiment Video

Updated: Apr 24, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

812

Pathogenesis and prognostication in acute lymphoblastic leukemia.

Tsila Zuckerman1, Jacob M Rowe2

  • 1Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus 8 Ha'Aliya Street, Haifa 31096 Israel ; Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology Efron Street, Haifa 31096 Israel.

F1000Prime Reports
|September 4, 2014
PubMed
Summary

Acute lymphoblastic leukemia (ALL) involves genetic mutations blocking normal lymphoid cell development. Next-generation sequencing reveals new mutations and epigenetic changes, aiding prognosis and targeted therapy for ALL patients.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

8.6K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.2K

Related Experiment Videos

Last Updated: Apr 24, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

812
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

8.6K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.2K

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Lymphoid maturation is a complex process regulated by transcription factors and signal transduction.
  • Acute lymphoblastic leukemia (ALL) is a malignancy of immature lymphoid cells caused by genetic alterations.
  • Recent advances in sequencing are uncovering new genetic and epigenetic factors in ALL.

Purpose of the Study:

  • To explore the role of genetic mutations and epigenetic alterations in Acute lymphoblastic leukemia (ALL).
  • To understand how these alterations impact normal lymphopoiesis and contribute to ALL development.
  • To highlight the utility of next-generation sequencing in identifying therapeutic targets for ALL.

Main Methods:

  • Utilizing next-generation sequencing (NGS) to identify mutations in lymphoid cells.
  • Analyzing cooperating mutations and epigenetic alterations.
  • Correlating genetic findings with patient prognosis and treatment strategies.

Main Results:

  • Identification of novel mutations affecting normal lymphopoiesis in ALL.
  • Understanding the significance of cooperating mutations in ALL pathogenesis.
  • Discovery of epigenetic alterations contributing to lymphoid malignancies.

Conclusions:

  • Next-generation sequencing provides crucial insights into the genetic landscape of ALL.
  • Identifying specific mutations aids in predicting patient prognosis.
  • This knowledge facilitates the development of targeted therapies for Acute lymphoblastic leukemia.